IRVING, Texas, Jan. 30 /PRNewswire-FirstCall/ -- Carrington Laboratories, Inc. (OTC Bulletin Board: CARN) said it retained Milkie/Ferguson Investments, Inc. as its financial advisor to assist it in exploring a range of financial alternatives.
"Our hiring of a financial advisor is a continuation of our efforts to thoroughly consider our business model and all opportunities going forward," said Carlton Turner, PhD, chief executive officer of Carrington. "We have valuable technologies and assets which we believe have significant emerging potential and we look forward to working with Milkie/Ferguson on these initiatives."
Carrington Laboratories, Inc. is an ISO 9001-certified, research-based, biopharmaceutical and consumer products company currently utilizing naturally-occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care, as well as to manufacture and market the nutraceutical raw material Manapol(R) and cosmetic raw material Hydrapol(TM). Carrington also manufactures and markets consumer products and manufactures quality products for other companies. Manufacturing operations comply with cGMP standards. Carrington's DelSite Biotechnologies subsidiary is developing its proprietary GelSite(R) polymer technology designed to provide controlled release of peptide and protein-based drugs. A second technology Gelvac(TM) is designed for dry powder nasal delivery of vaccines without the need for preservatives, adjuvants, cold storage and shipping under cold conditions. One influenza vaccine, (H1N1 antigen) with this technology, has been stable for more than three years at room temperature.
Carrington's technology is protected by more than 130 patents in 26
countries. Select products carry the CE mark, recognized by more than 20
countries around the world. For more information, visit
|SOURCE Carrington Laboratories, Inc.|
Copyright©2008 PR Newswire.
All rights reserved